Analysts Issue Multiple Stock Rating Changes
Analysts Issue Multiple Stock Rating Changes
Anonymous
Key Points
1
Jefferies raised Five Below’s price target from $350 to $420 and reaffirmed a buy rating, the highest target listed among the recent analyst actions.
2
APA’s analyst views span a wide range: Stifel Nicolaus initiated coverage with a buy rating and a $62 target, while Goldman Sachs reaffirmed a sell rating with a $43 target; UBS maintained neutral despite raising its target to $47.
3
Itau BBA analyst Pedro Leduc downgraded Nu Holdings from outperform to market perform and reduced the price target from $20 to $18; the shares had closed at $14.19 when the action was reported.
4
UBS analyst Tasso Vasconcellos downgraded Braskem from neutral to sell and slashed the price target from $4 to $1.50, below the company’s reported closing price of $2.10.
5
Barclays analyst Lukas Shumway cut Cellectis from overweight to underweight and reduced its price target from $9 to $1.30; Cellectis closed at $1.61 when the downgrade was reported.
Wall Street analysts issued a wave of rating changes this week, with Five Below emerging as the clear favorite after Jefferies raised its price target to $420 and reaffirmed a buy rating. Other stocks faced sharper criticism, including Braskem and Cellectis, which both suffered double-digit price-target cuts as analysts grew increasingly bearish on their outlooks.
The moves reflect diverging confidence across sectors. While some firms upgraded growth stocks like Medical Properties Trust and Netflix, others slashed targets for energy, biotech, and fintech names. Goldman Sachs maintained a sell on APA despite competitor upgrades, signaling deep disagreements on certain names.
Five Below Soars on Analyst Enthusiasm
Five Below drew broad support from Wall Street, with Jefferies setting the highest price target at $420—a significant uplift that underscores bullish sentiment. Multiple firms maintained buy or overweight ratings on the stock. However, Wall Street Zen downgraded the stock to hold, and Citigroup kept a neutral stance, showing cracks in the consensus.
APA Faces Sharply Divided Wall Street Views
Stifel Nicolaus initiated coverage on APA with a buy rating and $62 target, while UBS and Raymond James also raised their price targets. But Goldman Sachs pushed back hard, reaffirming a sell rating with a $43 target—a $19 gap that shows extreme disagreement. UBS kept a neutral rating despite raising its target to $47, reflecting caution even among bullish analysts.
Biotech and Fintech Stocks Face Brutal Downgrades
Itau BBA analyst Pedro Leduc downgraded Nu Holdings from outperform to market perform and slashed the price target from $20 to $18. The stock closed at $14.19, meaning it was already trading below the analyst's new target. This signals deeper weakness ahead, in his view.
Biotech name Cellectis took an even harder hit. Barclays analyst Lukas Shumway cut the stock from overweight to underweight and slashed the price target from $9 to $1.30—a 86% cut. Cellectis closed at $1.61 when the downgrade hit. UBS also downgraded Braskem from neutral to sell and cut its target from $4 to $1.50, far below the stock's $2.10 close.
Medical Properties Trust and Netflix Get Upgrades
Seeking Alpha reported that Medical Properties Trust earned an upgrade, with the analyst citing reduced refinancing risk and attractive valuation at current levels. Netflix also received an upgrade, though details on the specific rationale were limited. These upgrades came as growth stocks found renewed favor among some analysts.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
10
Reach
27
A
AnonymousAuthor
